Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress ...Middle East

PR Newswire - News
Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress
The study involved end-stage oncology patients with no other suitable treatment options. In this Phase Ib study, Pidnarulex (CX-5461) demonstrated acceptable clinical tolerability and showed preliminary signs of efficacy, even in patients who had previously failed treatment with PARP...

Hence then, the article about senhwa biosciences presents clinical data abstract on pidnarulex at 2024 esmo congress was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News